Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:INMB NASDAQ:MOLN NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.82-1.7%$9.46$3.75▼$11.54$157.32M2.7393,437 shs22,135 shsINMBINmune Bio$2.32-4.3%$5.83$1.89▼$11.64$54.82M1.34853,953 shs810,748 shsMOLNMolecular Partners$3.79+5.1%$3.77$3.36▼$12.22$152.84M1.114,434 shs697 shsVORVor Biopharma$2.13-3.8%$0.82$0.13▼$3.29$266.79M2.044.94 million shs2.72 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition0.00%-7.59%+9.06%+137.29%+998,999,900.00%INMBINmune Bio0.00%+4.76%-62.07%-66.76%-70.05%MOLNMolecular Partners0.00%+2.23%-1.52%-3.85%-44.92%VORVor Biopharma0.00%-11.60%+819.68%+221.97%+139.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition1.0827 of 5 stars3.50.00.00.00.00.80.0INMBINmune Bio1.5898 of 5 stars3.31.00.00.01.11.70.6MOLNMolecular Partners2.9495 of 5 stars3.85.00.00.00.00.00.6VORVor Biopharma3.9214 of 5 stars4.35.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00103.67% UpsideINMBINmune Bio 2.57Moderate Buy$18.40694.82% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00217.04% UpsideVORVor Biopharma 2.60Moderate Buy$5.63164.87% UpsideCurrent Analyst Ratings BreakdownLatest VOR, MOLN, ACOG, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold6/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform5/16/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/9/2025VORVor BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.005/9/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/8/2025VORVor BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/AINMBINmune Bio$10K5,458.77N/AN/A$1.45 per share1.60MOLNMolecular Partners$5.65M27.05N/AN/A$3.99 per share0.95VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.20N/A∞N/AN/A-65.83%-48.21%8/11/2025 (Estimated)INMBINmune Bio-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)MOLNMolecular Partners-$61.39M-$1.92N/AN/AN/AN/A-42.20%-38.12%8/25/2025 (Estimated)VORVor BiopharmaN/A-$1.51N/AN/AN/AN/AN/AN/AN/ALatest VOR, MOLN, ACOG, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ACOGAlpha Cognition-$0.84N/AN/AN/A$2.32 millionN/A8/7/2025Q2 2025INMBINmune Bio-$0.37N/AN/AN/AN/AN/A5/15/2025Q1 2025ACOGAlpha Cognition-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83INMBINmune BioN/A2.642.64MOLNMolecular PartnersN/A15.2815.28VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AINMBINmune Bio12.72%MOLNMolecular Partners26.55%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%INMBINmune Bio35.70%MOLNMolecular Partners5.93%VORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million13.78 millionN/AINMBINmune Bio1023.58 million15.17 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableVORVor Biopharma140124.96 million65.45 millionNot OptionableVOR, MOLN, ACOG, and INMB HeadlinesRecent News About These CompaniesVor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors4 hours ago | globenewswire.comH.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price TargetJuly 20 at 2:29 AM | msn.comVor Bio Grants Stock Options and RSUs to New Chief Development Officer Dr. Qing ZurawJuly 18 at 4:36 PM | quiverquant.comQVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 18 at 4:00 PM | globenewswire.comVor Bio Appoints Qing Zuraw, M.D. as Chief Development OfficerJuly 17, 2025 | globenewswire.comVor Biopharma Names Sandy Mahatme Chief Financial OfficerJuly 11, 2025 | marketwatch.comVor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business OfficerJuly 11, 2025 | finanznachrichten.deVor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business OfficerJuly 10, 2025 | globenewswire.comVor Biopharma: Not So Sure About This Surge, And Do Mind The WarrantsJuly 8, 2025 | seekingalpha.comBiopharma layoffs for first half of the year jump 32% YOYJuly 8, 2025 | fiercebiotech.comFVor Biopharma Target of Unusually High Options Trading (NYSE:VOR)July 8, 2025 | marketbeat.comBoston’s biotech sector reels due to Trump health policy uncertaintyJuly 6, 2025 | ft.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 5, 2025 | marketbeat.comVor Biopharma Q2 EPS Estimate Decreased by HC WainwrightJuly 2, 2025 | marketbeat.comVor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comHC Wainwright & Co. Upgrades Vor Biopharma (VOR)June 30, 2025 | msn.comVor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune MarketJune 30, 2025 | benzinga.comVor Bio Stock Skyrockets 250% in the Past Week: Here's WhyJune 30, 2025 | zacks.comVor Biopharma (NYSE:VOR) Upgraded at HC WainwrightJune 30, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Gains Momentum S&P 500June 27, 2025 | kalkinemedia.comKVor Biopharma Inc. Stock Grades - Barron'sJune 27, 2025 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhich Analyst-Favorite Drone Stock Will Come Out on Top?By Nathan Reiff | June 25, 2025View Which Analyst-Favorite Drone Stock Will Come Out on Top?Top Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure BoomMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceThis ASML Dip Could Be Gone Before You Know It—Don’t Miss OutBy Thomas Hughes | July 16, 2025View This ASML Dip Could Be Gone Before You Know It—Don’t Miss OutSizzling Insider Buys for Your High-Yield WatchlistBy Thomas Hughes | July 8, 2025View Sizzling Insider Buys for Your High-Yield WatchlistVOR, MOLN, ACOG, and INMB Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.82 -0.17 (-1.70%) As of 11:33 AM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.INmune Bio NASDAQ:INMB$2.32 -0.11 (-4.34%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Molecular Partners NASDAQ:MOLN$3.78 +0.19 (+5.14%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Vor Biopharma NYSE:VOR$2.12 -0.09 (-3.85%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.